PLC-β2 is highly expressed in breast cancer and is associated with a poor outcome: A study on tissue microarrays

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 863-872

  Bertagnolo, Valeria ^a   Benedusi, Mascia ^a   Querzoli, Patrizia ^a   Pedriali, Massimo ^a   Magri, Eros ^a   Brugnoli, Federica ^a   Capitani, Silvano ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Breast cancer; Phospholipase C 2; Prognostic factors; Tissue microarrays; Tumor markers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ISOENZYME; KI 67 ANTIGEN; PHOSPHOLIPASE C; PHOSPHOLIPASE C BETA; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; KI-67 ANTIGEN; MIDDLE AGED; PHOSPHOLIPASE C; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33744735676     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.863     Document Type: Article

References (43)

1. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339: 974-841, 1998.
2. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics 2001. CA Cancer J Clin 51: 15-36, 2001.
3. Wilson CM, Tobin S and Young RC: The exploding worldwide cancer burden: the impact of cancer on women. Int J Gynecol Cancer 14: 1-11, 2004.
4. Oved S and Yarden Y: Signal transduction: molecular ticket to enter cells. Nature 416: 133-136, 2002.
5. Rowinsky EK: Signal events: cell signal transduction and its inhibition in cancer. Oncologist 8: 5-17, 2003.
6. Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G and Page DL: Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci USA 88: 10435-10439, 1991.
7. Martelli AM, Billi AM, Gilmour RS, Neri LM, Manzoli L, Ognibene A and Cocco L: Phosphoinositide signaling in nuclei of Friend cells: phospholipase C beta down-regulation is related to cell differentiation. Cancer Res 54: 2536-2540, 1994.
8. Iiri T, Homma Y, Ohoka Y, Robishaw JD, Katada T and Bourne HR: Potentiation of Gi-mediated phospholipase C activation by retinoic acid in HL-60 cells. Possible role of G gamma 2. J Biol Chem 270: 5901-5908, 1995.
9. Nomoto K, Tomita N, Miyake M, Xhu DB, LoGerfo PR and Weinstein IB: Expression of phospholipases gamma 1, beta 1, and delta 1 in primary human colon carcinomas and colon carcinoma cell lines. Mol Carcinog 12: 146-152, 1995.
10. Lee SB, Rao AK, Lee KH, Yang X, Bae YS and Rhee SG: Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood 88: 1684-1691, 1996.
11. Bertagnolo V, Marchisio M, Capitani S and Neri LM: Intranuclear translocation of phospholipase C beta2 during HL-60 myeloid differentiation. Biochem Biophys Res Commun 235: 831-837, 1997.
12. Marchisio M, Di Baldassarre A, Angelucci D, et al: Phospholipase C delta2 expression characterizes the neoplastic transformation of the human gastric mucosa. Am J Pathol 159: 803-808, 2001.
13. Bertagnolo V, Marchisio M, Pierpaoli S, Colamussi ML, Brugnoli F, Visani G, Zauli G and Capitani S: Selective upregulation of phospholipase C-beta2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors. J Leukoc Biol 71: 957-965, 2002.
14. Stalberg P, Granberg D, Carling T, Wilander E, Eriksson B, Gobl A, Akerstrom G, Rastad J, Modlin IM, Oberg K and Skogseid B: In situ RNA-RNA hybridisation of phospholipase C beta 3 shows lack of expression in neuroendocrine tumours. Anticancer Res 23: 2227-2232, 2003.
15. Lo Vasco VR, Calabrese G, Manzoli L, Palka G, Spadano A, Morizio E, Guanciali-Franchi P, Fantasia D and Cocco L: Inositide-specific phospholipase C beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18: 1122-1126, 2004. (Pubitemid 38786971)
16. Leung DW, Tompkins C, Brewer J, Ball A, Coon M, Morris V, Waggoner D and Singer JW: Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells. Mol Cancer 13: 1-15, 2004.
17. Pozzobon M, Marafioti T, Hansmann ML, Natkunam Y and Mason DY: Intracellular signalling molecules as immunohistochemical markers of normal and neoplastic human leucocytes in routine biopsy samples. Br J Haematol 124: 519-533, 2004. (Pubitemid 38230599)
18. Kassis J, Moellinger J, Lo H, Greenberg NM, Kim HG and Wells A: A role for phospholipase C-gamma-mediated signaling in tumor cell invasion. Clin Cancer Res 5: 2251-2260, 1999.
19. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS and Brandt BH: Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 16: 1823-1825, 2002.
20. Katterle Y, Brandt BH, Dowdy SF, Niggemann B, Zanker KS and Dittmar T: Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. Br J Cancer 90: 230-235, 2004.
21. World Health Organization Classification of Tumours: Pathology and genetics of tumours of the breast and female genital organs. Tavassoli FA and Devilee P (eds). WHO, IARC, Lyon, 2003.
22. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
23. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Magri E and Nenci I: Quantitative immunoprofiles of breast cancer performed by image analysis. Anal Quant Cytol Histol 21: 151-160, 1999.
24. Lacroix M and Leclercq G: Relevance of breast cancer cell lines as models for breast tumours: An update. Breast Cancer Res Treat 83: 249-289, 2004.
25. Rebecchi MJ and Pentyala SN: Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev 80: 1291-1335, 2000.
26. Rhee SG: Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem 70: 281-312, 2001.
27. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP and Sauter G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-2256, 2001.
28. Zhang D, Salto-Tellez M, Do E, Putti TC and Koay ES: Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34: 362-368, 2003. (Pubitemid 36535020)
29. Grant GM, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP and Sauter G: Microarrays in cancer research. Anticancer Res 24: 441-448, 2004.
30. Jiang H, Kuang Y, Wu Y, Xie W, Simon MI and Wu D: Roles of phospholipase C beta2 in chemoattractant-elicited responses. Proc Natl Acad Sci USA 94: 7971-7975, 1997.
31. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV and Wu D: Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287: 1046-1049, 2000.
32. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F and Berger R: NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia. Blood 77: 1080-1086, 1991.
33. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S and Lippman ME: Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544, 1992.
34. Sommers CL, Byers SW, Thompson EW, Torri JA and Gelmann EP: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31: 325-335, 1994.
35. Schmid P, Wischnewsky MB, Sezer O, Bohm R and Possinger K: Prediction of response to hormonal treatment in metastatic breast cancer. Oncology 63: 309-316, 2002.
36. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
37. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001.
38. Van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, et al: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161: 1991-1996, 2002.
39. Sneige N: Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions. Diagn Cytopathol 30: 158-165, 2004.
40. Esteva FJ: Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9: 4-9, 2004.
41. Hinoda Y, Sasaki S, Ishida T and Imai K: Monoclonal antibodies as effective therapeutic agents for solid tumors. Cancer Sci 95: 621-625, 2004. (Pubitemid 39255807)
42. Nahta R and Esteva FJ: HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9: 5078-5084, 2003.
43. Gasco M, Shami S and Crook T: The p53 pathway in breast cancer. Breast Cancer Res 4: 70-76, 2002.